Pfizer's new obesity combo pill enters human testing
NCT ID NCT06924320
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two experimental drugs, MET233 and MET097, can help adults with obesity or overweight lose weight, including those with type 2 diabetes. About 381 participants will receive either the drug combination or a placebo to check safety and how well the body processes the drugs. The goal is to find a new treatment option for weight management.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Altasciences Clinical Los Angeles, Inc.
RECRUITINGCypress, California, 90630, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Coffee grounds probiotic could reshape gut health and fight inflammation